JMP Securities Reiterates Market Outperform on Elevation Oncology, Maintains $7 Price Target
Elevation Oncology, Inc. +2.35% Pre
Elevation Oncology, Inc. ELEV | 0.60 0.60 | +2.35% 0.00% Pre |
JMP Securities analyst Silvan Tuerkcan reiterates Elevation Oncology (NASDAQ:
ELEV) with a Market Outperform and maintains $7 price target.